Greenlight Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
$6.61M Buy
162,578
+6,200
+4% +$228K 0.32% 28
2023
Q3
$5.4M Buy
156,378
+6,210
+4% +$242K 0.31% 24
2023
Q2
$6.11M Sell
150,168
-1,200
-0.8% -$48.9K 0.29% 25
2023
Q1
$5.85M Sell
151,368
-3,990
-3% -$164K 0.32% 26
2022
Q4
$6.89M Buy
155,358
+8,970
+6% +$377K 0.48% 22
2022
Q3
$6.24M Hold
146,388
0.44% 23
2022
Q2
$8.17M Sell
146,388
-13,812
-9% -$819K 0.64% 24
2022
Q1
$9.94M Sell
160,200
-24,800
-13% -$1.52M 0.63% 28
2021
Q4
$10.2M Buy
+185,000
New +$9.65M 0.58% 26

Other funds holding LKFT

Greenlight Capital's LKFT Position: Q4 2023 in Review

Greenlight Capital increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 4% in Q4 2023, buying an estimated $228K and bringing the position to 162,578 shares worth $6.61M. The position accounts for 0.32% of the portfolio, ranked #28.

Greenlight Capital first reported a position in LKFT in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.2M in Q4 2021. 88 funds tracked by Wall St. Rank hold LKFT as of Q4 2023.

  • Greenlight Capital held 162,578 shares of Lakefront Biotherapeutics American Depositary Shares worth $6.61M as of Q4 2023.
  • Greenlight Capital bought 6,200 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2023, an estimated $228K.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.32% of Greenlight Capital's portfolio in Q4 2023, its #28 holding.
  • Greenlight Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2021 and has held it in 9 quarters since.
  • Greenlight Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $10.2M in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2023.

Based on Greenlight Capital's 13F filing for Q4 2023, filed 14 Feb 2024.